ArticlePloS one2015
Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring the Pharmacological Mechanism of the Effective Chinese Medicines Against Gynecological Cancer Based on Meta-Analysis Combined With Network Pharmacology Analysis.Frontiers in oncology · 2022Pooled it
- IID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks.Nucleic acids research · 2026Article
- Bioinformatics Analysis Identifies Lipid Droplet-Associated Gene Signatures as Promising Prognostic and Diagnostic Models for Endometrial Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Expression and prognosis of NR3C1 in uterine corpus endometrial carcinoma based on multiple datasets.Discover oncology · 2025Article
- Pyroptosis-Related Gene Signatures Enable Robustly Diagnosis, Prognosis and Immune Responses Prediction in Uterine Corpus Endometrial Carcinoma.Journal of Cancer · 2025Article
- Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value.NPJ biofilms and microbiomes · 2024Review
- Downregulation of RhoB Inhibits Cervical Cancer Progression and Enhances Cisplatin Sensitivity.Genes · 2024Article
- Integrative and comprehensive pan-cancer analysis of ubiquitin specific peptidase 11 (Heliyon · 2024Article
- Article
- A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.Scientific reports · 2024Article
- An Interaction Network Driven Approach for Identifying Cervical, Endometrial, Vulvar Carcinomic Biomarkers and Their Multi-targeted Inhibitory Agents from Few Widely Available Medicinal Plants.Applied biochemistry and biotechnology · 2023Article
- The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis.Biomedical reports · 2023Article
- TRIM28 modulates nuclear receptor signaling to regulate uterine function.Nature communications · 2023Article
- Article
- Immunogenetic Profiles and Associations of Breast, Cervical, Ovarian, and Uterine Cancers.Cancer informatics · 2023Article
- Article
- BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity.Journal of immunology research · 2022Article
- Functional New Transcription Factors (TFs) Associated with Cervical Cancer.Journal of healthcare engineering · 2022Article
- Integrative meta-analysis of gene expression profiles identifies FEN1 and ENDOU as potential diagnostic biomarkers for cervical squamous cell carcinoma.Oncology letters · 2021Article
- Metabolic rewiring is associated with HPV-specific profiles in cervical cancer cell lines.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies on individual types of gynecological cancers (GCs), utilizing novel expression technologies, have revealed specific pathogenetic patterns and gene markers for cervical (CC), endometrial (EC) and vulvar cancer (VC). Although the clinical phenotypes of the three types of gynecological cancers are discrete, the fact they originate from a common embryological origin, has led to the hypothesis that they might share common features reflecting regression to early embryogenesis. To address this question, we performed a comprehensive comparative analysis of their profiles. Our data identified both common features (pathways and networks) and novel distinct modules controlling the same deregulated biological processes in all three types. Specifically, four novel transcriptional modules were discovered regulating cell cycle and apoptosis. Integration and comparison of our data with other databases, led to the identification of common features among cancer types, embryonic stem (ES) cells and the newly discovered cell population of squamocolumnar (SC) junction of the cervix, considered to host the early cancer events. Conclusively, these data lead us to propose the presence of common features among gynecological cancers, other types of cancers, ES cells and the pre-malignant SC junction cells, where the novel E2F/NFY and MAX/CEBP modules play an important role for the pathogenesis of gynecological carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.